Biomedical Technology

Arbele Limited

🌍 Official Website 🏢 HKSTP Source
58 Potential

Decision Maker

N/A
enquiry.marketing@hkstp.org
+852 2629 1818
5/F, Building 5E, 5 Science Park East Avenue, Hong Kong Science Park
Raw Description
Arbele is a locally grown pharmaceutical biotech with over 30 scientists and staff focused on immunotherapy of advanced gastrointestinal cancers with a high mortality rate (such as liver, stomach, pancreas, oesophagus, colon and lung). The company is founded by accomplished, well-recognized scientists and senior executives from the pharmaceutical industry and teamed up with experienced professionals in business, accounting, finance and legal. | Arbele’s vision is to early detect and defeat gastrointestinal (GI) cancers with immunotherapeutics with breakthrough innovation. We strive to provide the first-in-class and best-in-class GI cancer drugs and premium in-vitro diagnostics for early disease intervention. Our exclusive worldwide patent coverage of CDH17, a novel target specific to the GI tract, means that we will be one of the leaders in the GI cancer field in providing a better, safer and cheaper treatment option to patients based on our range of robust pipelines on therapeutics and diagnostics products. | For more information: http://www.arbelebio.com || Product | Our founder Dr. John Luk discovered CDH17 to be a highly specific “clean target” biomarker in the GI tract. This biomarker is over-expressed in cancer cells and is clinically correlated to GI cancers progression. Our current pipeline includes bispecific antibody (ARB202), CDH17 immunodiagnostics and 5th generation AI-CAR-NK/T platform. | ARB202 is a first-in-class humanized bispecific antibody targeting CDH17 on tumour cells and CD3 on T cells, its first-in-human clinical trial is underway in Australia, and patient screening will take place in Hong Kong in Q3 2022. Further INDs are expected to be submitted to NMPA (China) and FDA (US) in 2023. | Technology | Arbele’s vision is to detect and defeat gastrointestinal (GI) cancers with immunotherapeutics with breakthrough innovations. We strive to provide the first-in-class and best-in-class GI cancer drugs and premium in-vitro diagnostics for early disease intervention. | Follow Us

Strategic Analysis

Executive Brief

Arbele Limited is a clinical-stage biopharmaceutical company specializing in immunotherapy and "breakthrough" in-vitro diagnostics (IVD) for gastrointestinal (GI) cancers. Their core innovation revolves around the CDH17 biomarker and advanced therapeutic platforms including bispecific antibodies (ARB202) and 5th-generation AI-enhanced CAR-NK/T cell therapies.

Strategic Fit & Lead Score

Lead Score: 58/100 (Adjacent Tech / Custom R&D)

Why this Score? While Arbele is primarily a drug-development firm, their focus on "premium in-vitro diagnostics" and "AI-CAR-NK/T platforms" creates a significant opening for 6C. Diamond is the ultimate material for bio-sensing due to its wide electrochemical window and biocompatibility. As Arbele moves from clinical trials to scaled diagnostics, they will face sensitivity bottlenecks and electrode fouling issues that 6C’s Boron-Doped Diamond (BDD) and Single-Crystal Diamond (SCD) technologies are uniquely positioned to solve.

6C Solutions Proposal

Application Area 6C Solution Technical Value Prop
Early-Stage Diagnostics BDD Electrochemical Sensors BDD electrodes provide the widest electrochemical window and lowest background noise, enabling the detection of CDH17 biomarkers at concentrations far below current industry standards.
Cell Therapy Monitoring NV-Center SCD Quantum Sensors Use 6C Single Crystal Diamond with Nitrogen-Vacancy centers to monitor real-time metabolic changes (pH, temperature, free radicals) within AI-CAR-NK cells without cell toxicity.
Microfluidics / Lab-on-Chip Diamond-on-Glass/Silicon Coating Proprietary MPCVD coating for diagnostic chips provides a protein-resistant, chemically inert surface that prevents "sticking" and ensures high-fidelity results for GI cancer screenings.
Drug Quality Control 9N Purity H2 Generators Support Arbele's analytical labs (Gas Chromatography/Mass Spec) with 6C’s ultra-high purity hydrogen generators, ensuring zero contamination in therapeutic batch testing.
Pharmaceutical Wastewater BDD Advanced Oxidation Systems BDD electrodes can mineralize complex organic pharmaceutical waste from antibody production onsite, reducing disposal costs and meeting strict environmental regulations.

Engagement Hooks

  • Technical Question: "As you scale your CDH17 immunodiagnostics, are you encountering limitations in signal-to-noise ratios or electrode fouling when testing complex GI patient samples? Our Boron-Doped Diamond (BDD) surfaces offer a non-fouling, high-sensitivity alternative to traditional gold or carbon electrodes."
  • Value Statement: "6C can help Arbele transition from standard diagnostics to 'Ultra-Sensitive' detection by integrating Diamond-based sensing tech, ensuring your CDH17 platform remains the gold standard for early-stage GI cancer intervention."